Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma. (Record no. 27231375)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 01862 a2200517 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250517155336.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 201807s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 1538-8514 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1158/1535-7163.MCT-16-0602-T |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Roth, Gaël S |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20180717 |
| 245 00 - TITLE STATEMENT | |
| Title | Efficacy of AKT Inhibitor ARQ 092 Compared with Sorafenib in a Cirrhotic Rat Model with Hepatocellular Carcinoma. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | Molecular cancer therapeutics |
| Date of publication, distribution, etc. | 10 2017 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 2157-2165 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Journal Article |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Aminopyridines |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Animals |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Apoptosis |
| General subdivision | drug effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Carcinoma, Hepatocellular |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Cell Line, Tumor |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Cell Proliferation |
| General subdivision | drug effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Disease Models, Animal |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Imidazoles |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Liver Cirrhosis |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Liver Neoplasms |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Niacinamide |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Oncogene Protein v-akt |
| General subdivision | antagonists & inhibitors |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Phenylurea Compounds |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Rats |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Signal Transduction |
| General subdivision | drug effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Sorafenib |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Macek Jilkova, Zuzana |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Zeybek Kuyucu, Ayca |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kurma, Keerthi |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ahmad Pour, Séyédéh Tayébéh |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Abbadessa, Giovanni |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Yu, Yi |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Busser, Benoit |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Marche, Patrice N |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Leroy, Vincent |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Decaens, Thomas |
| 773 0# - HOST ITEM ENTRY | |
| Title | Molecular cancer therapeutics |
| Related parts | vol. 16 |
| -- | no. 10 |
| -- | p. 2157-2165 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1158/1535-7163.MCT-16-0602-T">https://doi.org/10.1158/1535-7163.MCT-16-0602-T</a> |
| Public note | Available from publisher's website |
No items available.